August 17, 2020

Tocilizumab among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational Study

Category: Article Summary

Topic: Testing and Treatment

• Based on 210 patients with laboratory-confirmed COVID-19 in ICUs in New Jersey, receiving the drug tocilizumab was associated with a 40% reduction in mortality (aHR=0.6, 95%CI 0.5-0.9) compared with 420 propensity score-matched patients who did not receive tocilizumab. 

Biran et al. (Aug 14, 2020). Tocilizumab among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational Study. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(20)30277-0